Ryan Hudson is Vice President of Chemistry at UNITY, leading the chemical design of therapeutic molecules for the treatment of diseases of aging. Ryan joins UNITY with a drug discovery background in cardiovascular, antibacterial, immunology, central nervous system, and oncology research, and is co-inventor of over 20 patents. Prior to joining UNITY, Ryan was a medicinal chemistry team leader at Theravance Biopharma. Ryan led the medicinal chemistry team that discovered TD-1473, an orally administered pan-Janus kinase inhibitor designed to be intestinally restricted, which is currently in clinical development. Most recently, Ryan served as Associate Director of Chemistry at Corvus Pharmaceuticals. Ryan graduated from The University of Manchester, UK, with a Masters in Chemistry (MChem, first class honors). He also holds a Ph.D. in Chemistry from The University of Manchester, and then carried out his post-doctoral research at Stanford University.